Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.
Philippe MoreauCyrille HulinAurore PerrotBertrand ArnulfKarim BelhadjLotfi BenboubkerSonja ZweegmanHélène CaillonDenis CaillotHervé Avet-LoiseauMichel DelforgeThomas DejoieThierry FaconCécile SonntagJean FontanMohamad MohtyKon-Siong JieLionel KarlinFrédérique KuhnowskiJérôme LambertXavier LeleuMargaret MacroFrédérique Orsini-PiocelleMurielle RousselJean Marc Schiano de ColellaNiels Wcj van de DonkSoraya WuillèmeAnnemiek BroijlCyrille TouzeauMourad TiabJean-Pierre MarolleauNathalie MeulemanMarie-Christiane VekemansMatthijs WestermanSaskia K KleinMark-David LevinFritz OffnerMartine Escoffre-BarbeJean-Richard EveillardRéda GaridiWinnie HuaJianping WangAlba TuozzoCarla de BoerMelissa RoweVeronique VanquickelbergheRobin CarsonJessica VermeulenJill CorrePieter Sonneveldnull nullPublished in: The Lancet. Oncology (2024)
Intergroupe Francophone du Myélome, Dutch-Belgian Cooperative Trial Group for Hematology Oncology, and Janssen Research & Development.